Sysmex (OTCMKTS:SSMXY) Shares Gap Up – Still a Buy?

Shares of Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped up before the market opened on Tuesday . The stock had previously closed at $8.38, but opened at $8.78. Sysmex shares last traded at $8.78, with a volume of 90,388 shares changing hands.

Analysts Set New Price Targets

Separately, Citigroup cut Sysmex from a “strong-buy” rating to a “hold” rating in a report on Monday, March 16th. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold”.

Sysmex Price Performance

The stock has a market cap of $5.45 billion, a P/E ratio of 22.79 and a beta of 1.10. The firm has a 50-day moving average price of $8.66 and a 200-day moving average price of $9.31. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.44 and a current ratio of 3.33.

Sysmex (OTCMKTS:SSMXY) last announced its earnings results on Thursday, May 14th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02). Sysmex had a return on equity of 7.28% and a net margin of 7.13%.The firm had revenue of $877.92 million during the quarter, compared to the consensus estimate of $862.45 million. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. On average, analysts forecast that Sysmex Corporation ADR will post 0.37 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.